Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia.

CONCLUSION: Allo-HSCT is still the best-known treatment option with curative potential in patients with treatment-refractory AML. Therefore, all efforts should be made in an attempt to find a suitable matched donor in order to perform allo-HSCT.
PMID: 30616990 [PubMed - as supplied by publisher]

Source: Clinical Lymphoma and Myeloma - December 6, 2018 Category: Cancer & Oncology Authors: Ciftciler R, Demiroglu H, Buyukasık Y, Aladag E, Aksu S, Haznedaroglu IC, Sayınalp N, Ozcebe O, Malkan UY, Goker H Tags: Clin Lymphoma Myeloma Leuk Source Type: research